Trevena Expands Commercial and Medical Affairs Leadership Teams with Key Hires
CHESTERBROOK, Pa., June 11, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) announced today the recent additions of three key members to its leadership team. The Company has appointed Linda Wase, M.D. as Vice President of Medical Affairs, Michael Catalano as Vice President of Marketing, and Bob Yoder as Vice President of Sales & Commercial Operations.
Linda Wase, M.D., has worked with Trevena since 2017, first as a consultant guiding Medical Affairs strategy and, since March 2018, as Vice President of Medical Affairs. She has over 30 years of industry experience and has held multiple senior-level roles in Clinical Development and Medical Affairs, working at GlaxoSmithKline, Archimedes Pharma, King Pharmaceuticals, Bristol-Meyers Squibb, and Lederle Laboratories, among others. Dr. Wase is board certified in Internal Medicine.
Michael Catalano joined Trevena as Vice President of Marketing in February of this year. He brings a wealth of experience from Merck in US and global marketing, corporate licensing, and business development across oncology, vaccines, pain, and acute care/hospital. Mr. Catalano is also a licensed pharmacist in Pennsylvania.
Bob Yoder has joined Trevena as Vice President of Sales & Commercial Operations. He brings over 20 years of pharmaceutical industry experience in sales operations, sales, and business planning. After holding various commercial roles at Merck, Mr. Yoder was Senior Vice President & Head of Global Commercial Operations, Alliance Management & IT at Orexigen.
“We are excited to add three talented individuals to our team,” said Maxine Gowen, President & CEO. “Linda, Michael, and Bob each bring considerable industry experience and will play an instrumental role in advancing oliceridine and our other investigational products to help patients in need.”
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including oliceridine injection, for the management of moderate-to-severe acute pain, TRV250 for the treatment of acute migraine, and TRV734 for pain. The Company maintains an early stage portfolio of drug discovery programs.
Cautionary note on forward looking statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company’s clinical trials; the uncertainties inherent in conducting clinical trials; expectations for regulatory approvals, including for oliceridine; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; uncertainties related to the Company’s intellectual property; other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.
Jonathan Violin, Ph.D.
Sr. Vice President, Scientific Affairs & Investor Relations Officer
Released June 11, 2018